Castle Biosciences (CSTL) CCO Juvenal Tobin Sells Shares

What Happened
Juvenal Tobin W, Chief Commercial Officer of Castle Biosciences (CSTL), sold 1,301 shares on November 24, 2025 at $38.39 per share for total proceeds of $49,945. This was a sale (not a purchase or option exercise), which is commonly a routine disposition rather than a direct signal of company outlook.

Key Details

• Transaction date: 2025-11-24
• Type/code: Sale (S) — reported as "Open market or private sale"
• Price per share: $38.39; Shares sold: 1,301; Total proceeds: $49,945
• Footnote: Transaction executed pursuant to a Rule 10b5-1 trading plan adopted September 11, 2024 (pre‑scheduled plan).
• Shares owned after transaction: not specified in this filing.
• Filing timeliness: Report filed 2026-08-06 — approximately 8.5 months after the transaction (late filing).

Context
A 10b5-1 plan allows insiders to prearrange trades and is generally viewed as routine execution of a preexisting plan; it reduces the informational value of the sale for inferring insider sentiment. Sales are less informative than purchases for bullish signals. The late filing reduces near-term transparency about the trade but does not change the reported transaction details.